Strata Critical Medical (SRTA) Gains from Investment Securities (2019 - 2026)

Strata Critical Medical has disclosed Gains from Investment Securities across 8 years of filings, most recently posting -$78000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 500.0% year-over-year to -$78000.0; the TTM figure through Mar 2026 stood at -$5.4 million (down 9994.34% YoY), while the FY2025 annual figure was -$666000.0, down 1051.43% from the prior year.
• Gains from Investment Securities grew to -$78000.0 in Q1 2026, from -$5.2 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for SRTA reached as high as $2.5 million in Q2 2023 and fell as low as -$5.2 million in Q3 2025.
• The 5-year median for Gains from Investment Securities is -$13000.0 (2025), against an average of -$221230.8.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 256.22% — and 2026, when it tumbled 500.0%.
• A 5-year view of Gains from Investment Securities shows it stood at -$1.6 million in 2022, then soared by 207.74% to $1.7 million in 2023, then plunged by 95.88% to $70000.0 in 2024, then sank by 7521.43% to -$5.2 million in 2025, then soared by 98.5% to -$78000.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$78000.0, -$5.2 million, and -$77000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.